REGN Regeneron Pharmaceuticals Inc.

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

  • BMO Biopharma Spotlight Series: Oncology at 9:30 a.m. ET on Wednesday, November 8, 2023
  • Truist Securities BioPharma Symposium at 3:20 p.m. ET on Wednesday, November 8, 2023
  • UBS Biopharma Conference at 11:00 a.m. ET on Thursday, November 9, 2023

  • Jefferies London Healthcare Conference at 2:30 p.m. GMT (9:30 a.m. ET) on Wednesday, November 15, 2023

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. 

For additional information about Regeneron, please visit  or follow Regeneron on .

Contact Information:

Investor Relations

Ryan Crowe

914.847.8790



EN
25/10/2023

Underlying

REGNRegeneron Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for...

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron’s ongoing leadership in genetics-guided research and drug development to help people with serious diseases TARRYTOWN, N....

May 19, 2025 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

75th Annual Regeneron International Science and Engineering Fair Award...

75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition , 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world’s largest pre-college STEM competition in Columbus, Ohio TARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that , 19, of Dulovce, Slovakia, won the $100,000 George D. Yancopoulos Innov...

May 16, 2025 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Bi...

Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars in punitive damages TARRYTOWN, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) applauds the jury verdict in the U.S. District Court for the...

May 15, 2025 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo®...

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination 18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to Jun...

May 1, 2025 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Target...

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases 24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation Asthma abstracts include late-breaking data on mucus b...

May 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch